TABLE 3.
dnTCF4 |
Dkk1 |
Ex3 |
||||
EtOH | 4OHT | EtOH | 4OHT | EtOH | 4OHT | |
VM [mV] | −84.9 ± 0.7 | −87.1 ± 0.4** | −86.0 ± 0.6 | −89.1 ± 0.3*** | −86.10.3 | −85.50.6 |
IR [MΩ ] | 50.13.6 | 47.21.9 | 44.43.5 | 46.32.5 | 45.92.1 | 48.32.8 |
CM [pF] | 40.65.0 | 36.32.4 | 46.64.7 | 36.53.5 | 53.59.5 | 51.410.6 |
KIR/CM [pA/pF] | 2.40.4 | 1.90.3 | 2.90.6 | 4.20.6 | 2.00.3 | 2.10.3 |
KDR/CM [pA/pF] | 5.91.1 | 4.20.5 | 5.61.0 | 4.60.7 | 5.80.7 | 4.70.7 |
n | 25 | 40 | 23 | 32 | 39 | 30 |
4OHT, (Z)-4-hydroxytamoxifen; CM, membrane capacitance; Dkk1, Dickkopf 1; dnTCF4, dominant negative T-cell factor 4; EtOH, ethanol; Ex3, exon 3; IR, input resistance; KDR, delayed outwardly rectifying K+ currents; KIR, inwardly rectifying K+ currents; KIR/CM, KDR/CM, current densities; MCAO, middle cerebral artery occlusion; n, number of cells; NS/PCs, neural stem/progenitor cells; VM, membrane potential. Values in bold indicate significant differences between EtOH- and 4OHT-treated cultures; **p < 0.01, ***p < 0.001.